News

The Netherlands Antibiotic Development Platform (NADP) is organizing its second annual meeting, titled ‘Accelerating antibiotic development in Europe’.

Dutch biotechnology company Micreos announced it has secured €30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its breakthrough OTC Gladskin product for eczema.

Working antibiotics have given us a huge boost in quality of life over the last nine decades, but their importance and value is overlooked. Antibiotics play a crucial role in many more areas of life than most people imagine. This new report by ReAct and Dag Hammarskjöld Foundation looks at the state of global development when the drugs don’t work and a post-antibiotic era sets in. The report shows how antibiotic resistance is a global development problem by highlighting existing data and people’s experiences.

Antimicrobial resistance (AMR) is widely recognized as one of the 21st century’s greatest threats to health, welfare and food security. Worldwide, an estimated 700 000 people die each year from drug-resistant infections. In the European Union (EU) and European Economic Area (EEA) alone, 33 000 lives are claimed each year, and these numbers are rising.

Madam Therapeutics announced that it is one of the four companies in the Netherlands that have been awarded a novel grant from the Netherlands Antibiotic Development Platform (NADP).

Together with the World Health Organization (WHO), The Netherlands will organise a global conference in April 2019 about the fight against antibiotic resistance.